CCN2/CTGF is highly overexpressed in conditions associated with increased extracellular matrix (ECM) synthesis and fibrosis such as scleroderma (Sato et al. 2000; Yamamoto et al. 2005), diabetic nephropathy and kidney fibrosis (Mason 2013; Yin and Liu 2019), fibrotic liver diseases (Gressner and Gressner 2008), idiopathic pulmonary fibrosis (Richeldi et al. 2020), or glaucoma (Browne et al. 2011; Ho et al. 2020; Wallace et al. 2013). The gene discussed is CCN2; the disease is scleroderma.